Featured Study Opportunities
The Crohn's & Colitis Foundation utilizes Featured Study Opportunities to collaborate with academic and industry researchers to help enroll patients with Crohn’s disease and ulcerative colitis into clinical studies. The list below highlights our partners' current research studies. Please note that these partners have paid to have their trials posted below. Some partners' studies listed may be recipients of partial or full funding from the Crohn's & Colitis Foundation. This support does not imply recommendation or favor of the Foundation, as the Crohn's & Colitis Foundation does not endorse any particular study.
For a comprehensive listing of all research studies currently recruiting, please visit our IBD Clinical Trial Finder.
(For e.g NY instead of New York)
Current Results: 59 entries
Researchers in the BOOM-IBD Clinical Trial are exploring whether nerve stimulation, a therapy already approved by the FDA to treat other conditions, can be effective for treating Inflammatory Bowel Disease.
The goal of this study is to see if VE202 can help reduce inflammation in the large intestine and restore overall gut health in patients with mild to moderate ulcerative colitis. To study this, VE202 will be compared with a placebo.
Primary Objective: Induction
To evaluate the efficacy of cobitolimod treatment compared to placebo in inducing clinical remission, in participants with moderate to severe active left-sided UC.
Primary Objective: Maintenance
To evaluate the efficacy of cobitolimod maintenance treatment compared to placebo in inducing or maintaining clinical remission, in participants with clinical response at I-week 6 after induction treatment with cobitolimod.
To demonstrate that PredictSURE IBD can stratify an ethnically diverse North American population into high and low risk based on the need for early and frequent treatment escalations in the high-risk cohort.
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to < 18 years of age).
To characterize the safety and efficacy of ABBV-668 500mg by mouth (PO) twice a day (BID) as treatment in adult patients with moderately to severely active UC.
The hypothesis of this study is that the appropriate time of day of administration of oral, once-daily 5-ASA therapy in alignment with the participant’s circadian rhythms will improve subclinical inflammation and microbial structure/function and increase mucosal 5-ASA levels.
To understand the most important priorities of IBD patients who need surgery and quantify the reasons why patients consider delaying surgery, with potential reasons including, but not limited to lack of psychosocial support, gaps in knowledge, social stigma, burden to daily life, financial reasons, concerns about fertility, and mental well-being.
Primary Objective: Safety and Tolerability
Secondary Objective: Efficacy
Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system in adults. In this study, children and teenagers with moderate to severe ulcerative colitis will be treated with vedolizumab. The main aim of the study is to check if participants achieve remission after study treatment with vedolizumab. Remission means symptoms improve or disappear and an endoscopy shows no or limited signs of disease. Participants will receive 3 infusions of vedolizumab over 6 weeks. Then, those who have a clinical response will receive 1 of 3 doses of vedolizumab once every 8 weeks. They will receive the same dose every time.
The Featured Study Opportunities page is made possible in part by: